Verapamil, and its metabolite norverapamil, inhibit macrophage-induced, bacterial efflux pump-mediated tolerance to multiple anti-tubercular drugs

Journal of Infectious Diseases

Volumn 210, Issue 3, 2014, Pages 456-466

  Adams, Kristin N ^a   Szumowski, John D ^a   Ramakrishnan, Lalita ^a  

^a UNIVERSITY OF WASHINGTON   (United States)

Author keywords

Efflux; Efflux pump inhibitor; Norverapamil; Persistence; R verapamil; Tolerance; Tuberculosis; Verapamil

Indexed keywords

BEDAQUILINE; CAPREOMYCIN; CLOFAZIMINE; CYCLOSERINE; ETHAMBUTOL; ETHIONAMIDE; ISONIAZID; KANAMYCIN; LINEZOLID; MOXIFLOXACIN; NORVERAPAMIL; PRETOMANID; RIFABUTIN; RIFAMPICIN; STREPTOMYCIN; TUBERCULOSTATIC AGENT; VERAPAMIL; CALCIUM CHANNEL BLOCKING AGENT; THIORIDAZINE;

ARTICLE; BACTERIAL EFFLUX PUMP; BACTERIAL GROWTH; BACTERIAL PHENOMENA AND FUNCTIONS; CELL GROWTH; CELL LINE; DRUG INDICATION; DRUG INHIBITION; DRUG SENSITIVITY; DRUG TOLERABILITY; DRUG TOLERANCE; EXTENSIVELY DRUG RESISTANT TUBERCULOSIS; GROWTH INHIBITION; HUMAN; HUMAN CELL; ISOMERISM; MACROPHAGE; MACROPHAGE LIKE CELL LINE THP 1; MULTIDRUG RESISTANT TUBERCULOSIS; MYCOBACTERIUM TUBERCULOSIS; NONHUMAN; PHARMACOLOGICAL BLOCKING; PRIORITY JOURNAL; TREATMENT DURATION; ANALYSIS OF VARIANCE; ANTIBACTERIAL ACTIVITY; ANTIBIOTIC RESISTANCE; ANTIBIOTIC SENSITIVITY; BACTERIAL LOAD; BACTERIAL STRAIN; CHROMOSOME MUTATION; COLONY FORMING UNIT; CONCENTRATION RESPONSE; CONTROLLED STUDY; DRUG STRUCTURE; EX VIVO STUDY; MINIMUM INHIBITORY CONCENTRATION; MYCOBACTERIUM MARINUM;

EFFLUX; EFFLUX PUMP INHIBITOR; NORVERAPAMIL; PERSISTENCE; R-VERAPAMIL; TOLERANCE; TUBERCULOSIS; VERAPAMIL;

ANTITUBERCULAR AGENTS; BACTERIAL PROTEINS; CALCIUM CHANNEL BLOCKERS; CARRIER PROTEINS; CELL LINE; DRUG RESISTANCE, BACTERIAL; HUMANS; MACROPHAGES; MICROBIAL SENSITIVITY TESTS; MYCOBACTERIUM TUBERCULOSIS; VERAPAMIL;

EID: 84901061110     PISSN: 00221899     EISSN: 15376613     Source Type: Journal    
DOI: 10.1093/infdis/jiu095     Document Type: Article

References (50)

1. Controlled clinical trial of short-course (6-month) regimens of chemotherapy for treatment of pulmonary tuberculosis. Lancet 1972; 1: 1079-85.
2. Johnson JL, Hadad DJ, Dietze R, et al. Shortening treatment in adults with noncavitary tuberculosis and 2-month culture conversion. Am J Respir Crit Care Med 2009; 180:558-63.
3. Connolly LE, Edelstein PH, Ramakrishnan L. Why is long-term therapy required to cure tuberculosis? PLoS Med 2007; 4:e120.
4. Gomez JE, McKinney JD. M. tuberculosis persistence, latency, and drug tolerance. Tuberculosis 2004; 84:29-44.
5. Barry CE III, Boshoff HI, Dartois V, et al. The spectrum of latent tuberculosis: rethinking the biology and intervention strategies. Nat Rev Microbiol 2009; 7:845-55.
6. Stover CK,Warrener P, VanDevanter DR, et al. A small-molecule nitroimidazopyran drug candidate for the treatment of tuberculosis. Nature 2000; 405:962-6.
7. Andries K, Verhasselt P, Guillemont J, et al. A diarylquinoline drug active on the ATP synthase of Mycobacterium tuberculosis. Science 2005; 307:223-7.
8. Koul A, Vranckx L, Dendouga N, et al. Diarylquinolines are bactericidal for dormant mycobacteria as a result of disturbed ATP homeostasis. J Biol Chem 2008; 283:25273-80.
9. Diacon AH, Pym A, Grobusch M, et al. The diarylquinoline TMC207 for multidrug-resistant tuberculosis. N Engl J Med 2009; 360:2397-405.
10. Ibrahim M, Truffot-Pernot C, Andries K, Jarlier V, Veziris N. Sterilizing activity of R207910 (TMC207)-containing regimens in the murine model of tuberculosis. Am J Respir Crit Care Med 2009; 180:553-7.
11. Adams KN, Takaki K, Connolly LE, et al. Drug tolerance in replicating mycobacteria mediated by a macrophage-induced efflux mechanism. Cell 2011; 145:39-53.
12. Li XZ, Nikaido H. Efflux-mediated drug resistance in bacteria: an update. Drugs 2009; 69:1555-623.
13. Louw GE, Warren RM, Gey van Pittius NC, et al. Rifampicin reduces susceptibility to ofloxacin in rifampicin-resistant Mycobacterium tuberculosis through efflux. Am J Respir Crit Care Med 2011; 184:269-76.
14. Gupta S, Tyagi S, Almeida DV, Maiga MC, Ammerman NC, Bishai WR. Acceleration of tuberculosis treatment by adjunctive therapy with verapamil as an efflux inhibitor. Am J Respir Crit Care Med 2013; 188: 600-7.
15. Yajko DM, Madej JJ, Lancaster MV, et al. Colorimetric method for determining MICs of antimicrobial agents for Mycobacterium tuberculosis. J Clin Microbiol 1995; 33:2324-7.
16. Anonymous. Handbook of anti-Tuberculosis agents. Tuberculosis. Vol. 88:2. Edinburgh: Churchill Livingstone, 2008.
17. Balganesh M, Kuruppath S, Marcel N, Sharma S, Nair A, Sharma U. Rv1218c, an ABC transporter ofMycobacterium tuberculosis with implications in drug discovery. Antimicrob Agents Chemother 2010; 54:5167-72.
18. Dutta NK, Mehra S, Kaushal D. A Mycobacterium tuberculosis sigma factor network responds to cell-envelope damage by the promising anti-mycobacterial thioridazine. PLoS One 2010; 5:e10069.
19. Sharma S, Kumar M, Nargotra A, Koul S, Khan IA. Piperine as an inhibitor of Rv1258c, a putative multidrug efflux pump of Mycobacterium tuberculosis. J Antimicrob Chemother 2010; 65:1694-701.
20. Cao CX, Silverstein SC, Neu HC, Steinberg TH. J774 macrophages secrete antibiotics via organic anion transporters. J Infect Dis 1992; 165:322-8.
21. Zutshi RK, Singh R, Zutshi U, John RK, Atal CK. Influence of piperine on rifampicin blood levels in patients of pulmonary tuberculosis. J Assoc of Physicians India 1985; 33:223-4.
22. Rengarajan J, Bloom BR, Rubin EJ. Genome-wide requirements for Mycobacterium tuberculosis adaptation and survival in macrophages. Proc Natl Acad Sci U S A 2005; 102:8327-32.
23. Szumowski JD, Adams KN, Edelstein PH, Ramakrishnan L. Antimicrobial efflux pumps and Mycobacterium tuberculosis drug tolerance: evolutionary considerations. Curr Top Microbiol Immunol 2013; 374: 81-108.
24. Martins M, Viveiros M, Amaral L. Inhibitors of Ca2+ and K+ transport enhance intracellular killing of M. tuberculosis by non-killing macrophages. In Vivo 2008; 22:69-75.
25. Ordway D, Viveiros M, Leandro C, et al. Clinical concentrations of thioridazine kill intracellular multidrug-resistant Mycobacterium tuberculosis. Antimicrob Agents Chemother 2003; 47:917-22.
26. McTavish D, Sorkin EM. Verapamil: an updated review of its pharmacodynamic and pharmacokinetic properties, and therapeutic use in hypertension. Drugs 1989; 38:19-76.
27. Tfelt-Hansen P, Tfelt-Hansen J. Verapamil for cluster headache: clinical pharmacology and possible mode of action. Headache 2009; 49:117-25.
28. Schwartz JB, Todd E, Abernethy DR, Mitchell JR. Steady state verapamil tissue distribution in the dog: differing tissue accumulation. Pharmacology 1986; 32:307-12.
29. Solans C, Bregante MA, Aramayona JJ, Fraile LJ, Garcia MA. Comparison of the pharmacokinetics of verapamil in the pregnant and nonpregnant rabbit: study of maternal and foetal tissue levels. Xenobiotica 2000; 30:93-102.
30. Srinivasan K. Black pepper and its pungent principle-piperine: a review of diverse physiological effects. Crit Rev Food Sci Nutr 2007; 47:735-48.
31. Amaral L, Boeree MJ, Gillespie SH, Udwadia ZF, van Soolingen D. Thioridazine cures extensively drug-resistant tuberculosis (XDR-TB) and the need for global trials is now! Int J Antimicrob Agents 2010; 35:524-6.
32. McDermott W, Tompsett R. Activation of pyrazinamide and nicotinamide in acidic environments in vitro. Am Rev Tuberc 1954; 70:748-54.
33. Treatment of Tuberculosis Guidelines, 4th ed. World Health Organization, 2010.
34. Spies FS, da Silva PE, Ribeiro MO, Rossetti ML, Zaha A. Identification of mutations related to streptomycin resistance in clinical isolates of Mycobacterium tuberculosis and possible involvement of efflux mechanism. Antimicrob Agents Chemother 2008; 52:2947-9.
35. Louw GE, Warren RM, Gey van Pittius NC, McEvoy CR, Van Helden PDVictor TC. A balancing act: efflux/influx in mycobacterial drug resistance. Antimicrob Agents Chemother 2009; 53:3181-9.
36. Machado D, Couto I, Perdigao J, et al. Contribution of efflux to the emergence of isoniazid and multidrug resistance in Mycobacterium tuberculosis. PLoS One 2012; 7:e34538.
37. Singh M, Jadaun GP, Ramdas, et al. Effect of efflux pump inhibitors on drug susceptibility of ofloxacin resistant Mycobacterium tuberculosis isolates. Indian J Med Res 2011; 133:535-40.
38. Gupta S, Cohen KA, Winglee K, Maiga M, Diarra B, Bishai WR. Efflux inhibition with verapamil potentiates bedaquiline in Mycobacterium tuberculosis. Antimicrob Agents Chemother 2013; 58:574-6.
39. Ramaswamy S, Musser JM. Molecular genetic basis of antimicrobial agent resistance in Mycobacterium tuberculosis: 1998 update. Tuber Lung Dis 1998; 79:3-29.
40. Dhillon J, Andries K, Phillips PP, Mitchison DA. Bactericidal activity of the diarylquinoline TMC207 against Mycobacterium tuberculosis outside and within cells. Tuberculosis 2010; 90:301-5.
41. Pereira E, Teodori E, Dei S, Gualtieri F, Garnier-Suillerot A. Reversal of multidrug resistance by verapamil analogues. Biochem Pharmacol 1995; 50:451-7.
42. Neugebauer G. Comparative cardiovascular actions of verapamil and its major metabolites in the anaesthetised dog. Cardiovasc Res 1978; 12:247-54.
43. Busse D, Templin S, Mikus G, et al. Cardiovascular effects of (R)- and (S)-verapamil and racemic verapamil in humans: a placebo-controlled study. Eur J Clin Pharmacol 2006; 62:613-9.
44. Burman WJ, Goldberg S, Johnson JL, et al. Moxifloxacin versus ethambutol in the first 2 months of treatment for pulmonary tuberculosis. Am J Respir Crit Care Med 2006; 174:331-8.
45. Dorman SE, Johnson JL, Goldberg S, et al. Substitution of moxifloxacin for isoniazid during intensive phase treatment of pulmonary tuberculosis. Am J Respir Crit Care Med 2009; 180:273-80.
46. Abernethy DR, Wainer IW, Anacleto AI. Verapamil metabolite exposure in older and younger men during steady-state oral verapamil administration. Drug Metab Dispos 2000; 28:760-5.
47. Kuhn M, Schriger DL. Low-dose calcium pretreatment to prevent verapamil-induced hypotension. Am Heart J 1992; 124:231-2.
48. Barbarash R, Bauman J, Fischer J, Kondos G, Batenhorst R. Near-total reduction in verapamil bioavailability by rifampin: electrocardiographic correlates. Chest 1988; 94:954-9.
49. Siddiqi N, Das R, Pathak N, et al. Mycobacterium tuberculosis isolate with a distinct genomic identity overexpresses a tap-like efflux pump. Infection 2004; 32:109-11.
50. Beggs WH, Andrews FA. Inhibition of dihydrostreptomycin binding to Mycobacterium smegmatis by monovalent and divalent cation salts. Antimicrob Agents Chemother 1976; 9:393-6.